Paradoxical role for wild type p53 in driving therapy resistance in melanoma

Metastatic melanoma is an aggressive disease, despite recent improvements in therapy. Eradicating all melanoma cells even in drug-sensitive tumors is unsuccessful in patients because a subset of cells can transition to a slow-cycling state, rendering them resistant to most targeted therapy. It is st...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Mol Cell
Main Authors: Webster, Marie R, Fane, Mitchell E, Alicea, Gretchen M, Basu, Subhasree, Kossenkov, Andrew V, Marino, Gloria E, Douglass, Stephen M, Kaur, Amanpreet, Ecker, Brett L, Gnanapradeepan, Keerthana, Ndoye, Abibatou, Kugel, Curtis, Valiga, Alexander, Palmer, Jessica, Liu, Qin, Xu, Xiaowei, Morris, Jessicamarie, Yin, Xiangfan, Wu, Hong, Xu, Wei, Zheng, Cathy, Karakousis, Giorgos C, Amaravadi, Ravi K, Mitchell, Tara C, Almeida, Filipe V, Xiao, Min, Rebecca, Vito W, Wang, Ying-Jie, Schuchter, Lynn M, Herlyn, Meenhard, Murphy, Maureen E, Weeraratna, Ashani T
פורמט: Artigo
שפה:Inglês
יצא לאור: 2019
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7419227/
https://ncbi.nlm.nih.gov/pubmed/31836388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molcel.2019.11.009
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים